STING1 and central nervous system cancer: Since cyclic dinucleotide-based STING agonists display limited cellular uptake, intrinsic instability and a short blood circulation half-life [33,34], we further incorporated a non-nucleotide STING agonist into the cavity of RGE-HFn NPs to enhance its delivery into intracranial glioma sites and improve therapeutic outcomes.